Literature DB >> 31280272

Inherited Retinal Disorders: Using Evidence as a Driver for Implementation.

Panagiotis I Sergouniotis1,2,3.   

Abstract

Incremental advances in the field of retinal genetics have transformed our understanding of inherited retinal disorders and have led to the development of powerful diagnostic tests and promising gene-based therapies. Despite this, successful integration of these developments into routine healthcare is frequently ineffective. Providing robust evidence of benefit can accelerate the implementation of clinical genetic interventions. For example, the adoption of a genetic test is much more likely when the test's clinical utility (i.e. its ability to influence management and health outcomes) has been clearly demonstrated. However, accruing such evidence for rare conditions like inherited retinal disorders is challenging. Conducting sufficiently powered studies requires both efficient study designs and large-scale, international collaboration. Reaching all populations and as many affected individuals as possible is key. Equally important are efforts to precisely and consistently capture phenotypic information, including natural history data. This article summarizes some of the current obstacles to implemen-tation and discusses approaches to overcome these barriers.
© 2019 S. Karger AG, Basel.

Entities:  

Keywords:  Clinical utility; Evidence-based medicine; Genomic medicine; Implementation science; Inherited retinal disease; Rare eye disease

Year:  2019        PMID: 31280272     DOI: 10.1159/000500574

Source DB:  PubMed          Journal:  Ophthalmologica        ISSN: 0030-3755            Impact factor:   3.250


  4 in total

1.  Clinical utility of genetic testing in 201 preschool children with inherited eye disorders.

Authors:  Eva Lenassi; Jill Clayton-Smith; Sofia Douzgou; Simon C Ramsden; Stuart Ingram; Georgina Hall; Claire L Hardcastle; Tracy A Fletcher; Rachel L Taylor; Jamie M Ellingford; William D Newman; Cecilia Fenerty; Vinod Sharma; I Chris Lloyd; Susmito Biswas; Jane L Ashworth; Graeme C Black; Panagiotis I Sergouniotis
Journal:  Genet Med       Date:  2019-12-18       Impact factor: 8.822

2.  The need for widely available genomic testing in rare eye diseases: an ERN-EYE position statement.

Authors:  Graeme C Black; Panagiotis Sergouniotis; Andrea Sodi; Bart P Leroy; Caroline Van Cauwenbergh; Petra Liskova; Karen Grønskov; Artur Klett; Susanne Kohl; Gita Taurina; Marius Sukys; Lonneke Haer-Wigman; Katarzyna Nowomiejska; João Pedro Marques; Dorothée Leroux; Frans P M Cremers; Elfride De Baere; Hélène Dollfus
Journal:  Orphanet J Rare Dis       Date:  2021-03-20       Impact factor: 4.123

3.  Patient-Reported Health-Related Quality of Life in Individuals with Inherited Retinal Diseases.

Authors:  Deborah Schofield; Joshua Kraindler; Owen Tan; Rupendra Shrestha; Diana Jelovic; Sarah West; Alan Ma; John Grigg; Robyn V Jamieson
Journal:  Ophthalmol Sci       Date:  2021-12-23

4.  The Impact of Inherited Retinal Diseases in the United States of America (US) and Canada from a Cost-of-Illness Perspective.

Authors:  Jennifer Gong; Simone Cheung; Alivia Fasso-Opie; Orla Galvin; Larissa S Moniz; Doug Earle; Todd Durham; Jason Menzo; Nan Li; Stephanie Duffy; Jill Dolgin; Mark S Shearman; Chiara Fiorani; Judit Banhazi; Avril Daly
Journal:  Clin Ophthalmol       Date:  2021-07-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.